Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according…
